Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
PTC Therapeutics, Inc. (PTCT)  
$37.20 0.07 (0.19%) as of 4:30 Fri 5/24


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 90,552,000
Market Cap: 3.37(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $18.07 - $45.015
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 8
Insider 3/6 Months : 8.6
Guru Rank Number :  538
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 7,700 7,700 7,700
Total Buy Value $0 $198,736 $198,736 $198,736
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 1 1
Total Shares Sold 6,156 52,347 65,013 280,515
Total Sell Value $156,968 $1,453,245 $1,963,077 $12,893,521
Total People Sold 3 8 9 15
Total Sell Transactions 5 27 29 89
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 568
  Page 19 of 23  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Peltz Stuart Walter Chief Executive Officer   •       •      –    2015-06-09 4 AS $52.89 $1,401,617 D/D (26,300) 3,776     -
   Peltz Stuart Walter Chief Executive Officer   •       •      –    2015-06-09 4 OE $10.85 $285,355 D/D 26,300 30,076     -
   Aldrich Richard Director   –       •      –    2015-06-08 4 AS $55.65 $389,592 D/D (7,000) 0     -
   Aldrich Richard Director   –       •      –    2015-06-08 4 OE $10.85 $75,950 D/D 7,000 7,000     -
   Peltz Stuart Walter Chief Executive Officer   •       •      –    2015-06-08 4 AS $53.81 $4,047,174 D/D (73,700) 3,776     -
   Peltz Stuart Walter Chief Executive Officer   •       •      –    2015-06-08 4 OE $10.85 $840,615 D/D 77,476 77,476     -
   Boulding Mark Elliott Exec VP and CLO   •       –      –    2015-06-08 4 AS $53.87 $3,128,737 D/D (56,849) 16,327     -
   Boulding Mark Elliott Exec VP and CLO   •       –      –    2015-06-08 4 OE $10.85 $673,601 D/D 62,083 73,176     -
   Kovacs Shane William Charles Chief Financial Officer   •       –      –    2015-05-22 4 AS $55.26 $4,570,814 D/D (82,491) 8,850     -
   Kovacs Shane William Charles Chief Financial Officer   •       –      –    2015-05-22 4 OE $10.85 $1,158,632 D/D 78,991 91,341     -
   Schmertzler Michael Director   –       •      –    2015-05-19 4 D $0.00 $0 I/I (136) 0     -
   Schmertzler Michael Director   –       •      –    2015-05-18 4 D $0.00 $0 I/I (2,852) 136     -
   Schmertzler Michael Director   –       •      –    2015-05-15 4 D $0.00 $0 I/I (733) 2,988     -
   Schmertzler Michael Director   –       •      –    2015-05-11 4 D $0.00 $0 I/I (848) 3,721     -
   Schmertzler Michael Director   –       •      –    2015-05-07 4 D $0.00 $0 I/I (1,125,722) 4,569     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2015-04-15 4 AS $68.35 $652,913 D/D (9,511) 0     -
   Peltz Stuart Walter Chief Executive Officer   •       •      –    2015-03-23 4 AS $68.96 $3,263,428 D/D (47,200) 0     -
   Southwell David P Director   –       •      –    2015-03-23 4 AS $68.99 $159,957 D/D (2,317) 8,604     -
   Boulding Mark Elliott Exec. VP and CLO   •       –      –    2015-03-20 4 AS $67.77 $1,440,247 D/D (21,142) 11,093     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2015-03-19 4 AS $69.36 $1,426,240 D/D (20,370) 9,511     -
   Jacobson Allan Steven Director   –       •      –    2015-03-18 4 AS $74.75 $1,262,790 D/D (16,616) 11,848     -
   Rothera Mark Chief Commercial Officer   •       –      –    2015-03-17 4 AS $76.64 $820,048 D/D (10,700) 0     -
   Rothera Mark Chief Commercial Officer   •       –      –    2015-03-17 4 OE $10.85 $116,095 D/D 10,700 10,700     -
   Kranda Michael L Director   –       •      –    2015-03-16 4 AS $72.61 $182,037 D/D (2,500) 2,242     -
   Spiegel Robert J. Chief Medical Officer   •       –      –    2015-03-13 4 AS $75.10 $77,355 D/D (1,030) 3,239     -
  568 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 19 of 23
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us